Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model

The Journal of Surgical Research
Min GaoMingshi Yang

Abstract

Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, in gut barrier failure during experimental peritonitis in rats. Male rats were randomly divided into three groups as follows: sham, sepsis, and sepsis + pioglitazone. Sepsis was achieved by means of the cecal ligation and puncture (CLP). Pioglitazone was administered intraperitoneally (10 mg/kg/d) for 7 d before the experiment. Animals were killed at 24 h or followed 72 h for survival. The tissue level of tumor necrosis factor-α, interleukin-6, superoxide dismutase, malondialdehyde, and myeloperoxidase was measured. Intestinal mucosa injury was assessed histologically. The plasma fluorescein isothiocyanate-dextran, D-lactic acid, and intestinal diamine oxidase were determined to evaluate the permeability and integrity of intestinal mucosal epithelium. Vena cava blood and tissue samples were used to monitor bacterial translocation. Intestinal inflammation, oxidize stress, neutrophil infiltration, morphology injury, and impaired permeability of the small intestine in the CLP group were found more severe than tho...Continue Reading

References

Jan 1, 1987·JPEN. Journal of Parenteral and Enteral Nutrition·J S ThompsonL F Rikkers
Oct 1, 1986·The Journal of Infectious Diseases·S M SmithF Buccini
Aug 1, 1980·The Journal of Surgical Research·K A WichtermanI H Chaudry
Feb 24, 2001·Shock·H T HassounF A Moore
May 25, 2001·Current Opinion in Critical Care·E A Deitch
Jan 10, 2003·The New England Journal of Medicine·Richard S Hotchkiss, Irene E Karl
Nov 24, 2004·The Journal of Surgical Research·G M KoksalH Uzun
May 14, 2005·Proceedings of the National Academy of Sciences of the United States of America·Makoto AritaCharles N Serhan
Dec 24, 2005·Shock·William J HubbardIrshad H Chaudry
Jul 13, 2006·FEMS Immunology and Medical Microbiology·Shuhei Sakaguchi, Shinobu Furusawa
Jun 3, 2009·Biochemical and Biophysical Research Communications·Mikihito KajiyaToshihisa Kawai
Jul 3, 2009·American Journal of Physiology. Gastrointestinal and Liver Physiology·Jessica A ClarkCraig M Coopersmith
Jun 26, 2010·The Journal of Clinical Investigation·Filip K SwirskiMatthias Nahrendorf
Apr 20, 2012·Trends in Endocrinology and Metabolism : TEM·Bertrand CariouBart Staels
Apr 27, 2012·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·Edwin A Deitch
May 24, 2012·The New England Journal of Medicine·Richard P Wenzel, Michael B Edmond
Jan 24, 2013·The Journal of Surgical Research·Saad Shebrain, Amit Ramjit
Apr 3, 2013·The Journal of Surgical Research·Cong ZouXueming Huang
Dec 11, 2013·Frontiers in Pharmacology·Marina Kawaguchi-Suzuki, Reginald F Frye
Apr 10, 2014·The Journal of Surgical Research·Masahiko KutsukakeEiji Uchida

❮ Previous
Next ❯

Citations

Jan 9, 2016·Naunyn-Schmiedeberg's Archives of Pharmacology·Arnica BehringerEvren Caglayan
Dec 30, 2015·PPAR Research·Amanda CroasdellRichard P Phipps
Mar 10, 2017·Anesthesia and Analgesia·Robert H Thiele
Apr 12, 2016·Critical Care Medicine·Catherine S SassoonHamid M Said
Sep 7, 2018·Experimental and Therapeutic Medicine·Peng GuoFang Wu
Dec 12, 2017·International Journal of Experimental Pathology·Francielle B D FerreiraAlex Rafacho
Apr 12, 2019·European Journal of Pharmacology·Adriana Ribeiro SilvaVinicius de Frias Carvalho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here